RenovoRx, Inc.

NasdaqCM RNXT

RenovoRx, Inc. Price to Sales Ratio (P/S) on January 14, 2025

RenovoRx, Inc. Price to Sales Ratio (P/S) is NA on January 14, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • RenovoRx, Inc. 52-week high Price to Sales Ratio (P/S) is NA on January 14, 2025, which is NA below the current Price to Sales Ratio (P/S).
  • RenovoRx, Inc. 52-week low Price to Sales Ratio (P/S) is NA on January 14, 2025, which is NA below the current Price to Sales Ratio (P/S).
  • RenovoRx, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is NA.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Loading...
NasdaqCM: RNXT

RenovoRx, Inc.

CEO Mr. Shaun R. Bagai
IPO Date Aug. 26, 2021
Location United States
Headquarters 4546 El Camino Real
Employees 8
Sector Health Care
Industries
Description

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Similar companies

SABS

SAB Biotherapeutics, Inc.

USD 3.55

-3.00%

VRAX

Virax Biolabs Group Limited

USD 2.29

-3.78%

NTRB

Nutriband Inc.

USD 4.16

-1.65%

MNPR

Monopar Therapeutics Inc.

USD 24.98

-2.76%

ELDN

Eledon Pharmaceuticals, Inc.

USD 3.71

-4.63%

ADIL

Adial Pharmaceuticals, Inc.

USD 1.02

0.99%

ANEB

Anebulo Pharmaceuticals, Inc.

USD 1.60

5.96%

LGVN

Longeveron Inc.

USD 1.81

2.26%

KTTA

Pasithea Therapeutics Corp.

USD 2.53

-3.44%

IKNA

Ikena Oncology, Inc.

USD 1.51

-1.95%

StockViz Staff

January 15, 2025

Any question? Send us an email